Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas

Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas

Pediatric ependymomas are a type of malignant brain tumor that occurs in children. The overall 10-year survival rate has been reported as being 45–75%. Maximal safe surgical resection combined with adjuvant chemoradiation therapy is associated with the highest overall and progression-free survival r...

Full description

Bibliographic Details
Main Authors: Muh-Lii Liang, Chun-Han Chen, Yun-Ru Liu, Man-Hsu Huang, Yu-Chen Lin, Tai-Tong Wong, Sey-En Lin, Shing-Shiung Chu, Yi-Huei Ding, Tsung-Han Hsieh
Format: Article
Language:English
Published: MDPI AG 2020-12-01
Series:Cancers
Subjects:
pediatric ependymomas
abemaciclib
patient-derived xenografts
Online Access:https://www.mdpi.com/2072-6694/12/12/3597

Similar Items

Similar Items